Cytotoxicity of Nanoliposomal Cisplatin Coated with Synthesized Methoxypolyethylene Glycol Propionaldehyde in Human Ovarian Cancer Cell Line A2780CP
Purpose: To evaluate the cytotoxicity of pegylated nanoliposomal cisplatin on human ovarian cancer cell line A2780CP.
Methods: Synthesized methoxypolyethylene glycol (mPEG) propionaldehyde was characterized by 1Hnuclear magnetic resonance (1H-NMR) and Fourier transform infrared spectroscopy (FTIR) and used as coating agent for the preparation of liposomal nanodrug formulation by reverse phase evaporation method. The characteristics of the nanoparticles were evaluated by dynamic light scattering (DLS) and scanning electron microscopy (SEM). Encapsulation efficiency was determined spectrometrically at 214.42 nm by inductively coupled plasma spectroscopy (ICP-OES). The cytotoxicity of both pegylated nanoliposomal and free cisplatin were evaluated by 3- [4, 5 dimethyl-2-thiazolyl] -2, 5- diphenyltetrazolium bromide (MTT) assay and expressed as half-maximal inhibitory concentration (IC50).
Results: The mean diameter and zeta potential of drug-loaded liposomal particles and empty nanoliposomes were 125 ± 2.9 nm and -16.6 mV, 108 ± 2.2 nm and -27.2 mV, respectively, while the cytotoxicity (IC50) of free cisplatin and nanodrug formulation were 93.6 ± 3.1 μg/mL and 67.8 ± 2.3 μg/mL, respectively. In vitro toxicological results indicate that the formulation exhibited approximately 1.4-fold cytotoxicity compared with the free drug. Drug encapsulation efficiency of the nanoliposomes was approximately 98 ± 1 %.
Conclusion: The findings show that the cytotoxicity of pegylated nanoliposomal cisplatin is higher than that of free cisplatin in human ovarian cancer cell line A2780CP. In vivo studies are, however, required to ascertain its therapeutic potentials.
Keywords: Liposome, Nanodrug, Ovarian cancer, Polyethylene glycol, Cisplatin, Drug delivery, Cytotoxicity